Abstract
Intact SWA11 antibody was evaluated as a potential radioimmunotherapeutic agent against small cell lung cancer xenografts in a nude mouse model system. 131I-labelled SWA11 was given either in a single injection regimen (1 x 300 microCi) or as a multiple injection regimen achieving a total of 900 microCi (3 x 300 microCi with a 2 week interval between injections). Treatment of both small (mean volume approximately 0.2 cm3) and large (mean volume approximately 1.0 cm3) established xenografts resulted in significant anti-tumour effects and, in the case of the fractionated protocol, the failure of the xenografts to regrow within the period of observation (84 days). Xenograft histology following radioimmunotherapy showed large areas of necrosis, fibrosis and very few residual cells of SCLC origin.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cheung N. K., Landmeier B., Neely J., Nelson A. D., Abramowsky C., Ellery S., Adams R. B., Miraldi F. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst. 1986 Sep;77(3):739–745. doi: 10.1093/jnci/77.3.739. [DOI] [PubMed] [Google Scholar]
- Dykes P. W., Bradwell A. R., Chapman C. E., Vaughan A. T. Radioimmunotherapy of cancer: clinical studies and limiting factors. Cancer Treat Rev. 1987 Jun;14(2):87–106. doi: 10.1016/0305-7372(87)90042-9. [DOI] [PubMed] [Google Scholar]
- Kopper L., Steel G. G. The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res. 1975 Oct;35(10):2704–2713. [PubMed] [Google Scholar]
- Schlom J., Molinolo A., Simpson J. F., Siler K., Roselli M., Hinkle G., Houchens D. P., Colcher D. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990 May 2;82(9):763–771. doi: 10.1093/jnci/82.9.763. [DOI] [PubMed] [Google Scholar]
- Sharkey R. M., Pykett M. J., Siegel J. A., Alger E. A., Primus F. J., Goldenberg D. M. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res. 1987 Nov 1;47(21):5672–5677. [PubMed] [Google Scholar]
- Smith A., Waibel R., Westera G., Martin A., Zimmerman A. T., Stahel R. A. Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br J Cancer. 1989 Feb;59(2):174–178. doi: 10.1038/bjc.1989.36. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stahel R. A., Speak J. A., Bernal S. D. Murine monoclonal antibody LAM2 defines cell membrane determinant with preferential expression on human lung small-cell carcinoma and squamous-cell carcinomas. Int J Cancer. 1985 Jan 15;35(1):11–17. doi: 10.1002/ijc.2910350104. [DOI] [PubMed] [Google Scholar]
- Yoneda S., Fujisawa M., Watanabe J., Okabe T., Takaku F., Homma T., Yoshida K. Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody. Br J Cancer. 1988 Sep;58(3):292–295. doi: 10.1038/bjc.1988.206. [DOI] [PMC free article] [PubMed] [Google Scholar]